On August 15, a large number of listed pharmaceutical companies in Shanghai and Shenzhen issued important announcement.
Among them, 3 listed pharmaceutical companies disclosed their performance in the first half of the year, and 2 achieved growth, namely Darentang and Chengda Pharmaceutica.
Darentang: Net profit increased by 35% year-on-year
Darentang: Net profit increased by 35% year-on-year
Darentang released a semi-annual performance repor.
In the first half of 2022, the company achieved operating income of 775 billion yuan, a year-on-year increase of 69%, net profit of 469 million yuan, a year-on-year increase of 35%, and basic earnings per share of 61 yua.
According to the data, Darentang’s main business is Chinese patent medicine, Chinese herbal medicine, chemical raw materials and preparations, biomedicine, nutrition and health products R&D and manufacturing and pharmaceutical busines.
Chengda Pharmaceutical: Net profit increased by 279% year-on-year
Chengda Pharmaceutical: Net profit increased by 279% year-on-year
According to the 2022 semi-annual report of Chengda Pharmaceutical, the company achieved operating income of 217 million yuan in the first half of the year, a year-on-year increase of 131%; the net profit attributable to shareholders of the listed company was 6091 million yuan, a year-on-year increase of 279.
Basic earnings per share was 7024 yua.
As for the reasons for the growth in performance, the company explained that during the reporting period, with the continuous expansion and enrichment of the company's R&D product pipeline and the continuous improvement of R&D capabilities, the automation transformation of workshop equipment in the Huanghe Road factory area continued to be completed, driving the continuous improvement of product delivery capabilitie.
At the same time, the company developed some customized new drug intermediate projects, and the company's performance continued to grow with the listing of the project's terminal drug.
In addition, L-carnitine series products achieved stable production during the reporting period, with a year-on-year increase of 77% in output and a year-on-year increase of 625% in sale.
According to the data, Chengda Pharmaceutical is an enterprise mainly committed to providing CDMO services of key pharmaceutical intermediates for multinational pharmaceutical companies and pharmaceutical R&D institutions, and engaged in the R&D, production and sales of L-carnitine series product.
Joy Heart Health: Net profit turned from profit to loss
Joy Heart Health: Net profit turned from profit to loss
Yuexin Health announced that in the first half of the year, the company achieved operating income of 499 million yuan, a year-on-year decrease of 138%; the net loss attributable to shareholders of the listed company was 6088 million yuan, which turned from profit to loss year-on-yea.
Basic earnings per share -0093 yuan per shar.
Regarding the reasons for the decline in performance, the company stated that during the reporting period, due to the impact of the epidemic and the sluggish downstream real estate market, orders from customers in the real estate engineering channel dropped sharpl.
At the same time, due to the increased competition in the sales price of ceramic tiles, the cost of raw materials and the price of natural gas, the main production factor, have rise.
Under the combined influence of various factors, the company's building materials business has been greatly affecte.
It is understood that Yuexin Health is an enterprise that started with ceramic building material.
In October 2015, the company expanded into the big health industry combining medical care and health care, and made frequent moves in the new direction of "big health.
According to the data, the company's current business is divided into building materials, health care, medical services, investment real estate leasing,et.
Among them, in the health care business, the company seized market opportunities and actively deployed the health care industr.
At present, the company's "medium-to-high-end health care service" product line operated, constructed and planned includes "Yuexin-Manhuo Xincheng", "Yuexin-Anyi Bieye", and "Yuexin Care Training Center.
The three product lines support and rely on each other, forming a development trend that goes hand in han.
In terms of medical business, the company adopts both self-construction and self-operation and external mergers and acquisitions, including general hospitals and women's medical service.
The self-built and self-operated business mainly focuses on the field of medical cosmetology, with the chain of specialized hospitals as the development directio.
The medical institutions and cooperation projects that the company has successively invested in include: Quanjiao Tongde Love Hospital in Anhui Province, Fenjinting Hospital in Sihong County, Jiangsu Province, Anyi Hospital in Sihong in Jiangsu Province, Shanghai Yuexin General Outpatient Department, American Sunstar Reproductive Center, Jiangxi The Maternity and Reproductive Cooperation Project of Yichun Maternal and Child Health Hospital,et.
